[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649113":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":11,"centralContacts":37,"locations":43,"responsibleParty":65,"collaborators":11,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":11,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":11,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":11,"overallStatus":84,"whyStopped":11,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Jiangsu vcare pharmaceutical technology co., LTD","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"VC004 low dose group","EXPERIMENTAL",null,[13],"Drug: VC004 low dose",{"label":15,"type":10,"description":11,"interventionNames":16},"VC004 high dose group",[17],"Drug: VC004 high dose",{"label":19,"type":20,"description":11,"interventionNames":21},"VC004 placebo group","PLACEBO_COMPARATOR",[22],"Drug: VC004 placebo",[24,29,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","VC004 low dose","VC004 low dose BID",[9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"VC004 high dose","VC004 high dose BID",[15],{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"VC004 placebo","VC004 placebo BID",[19],[38],{"name":39,"role":40,"phone":41,"phoneExt":11,"email":42},"xiaojuan lai","CONTACT","+8615358160458","lai_xiaojuan@vcarepharmatech.com",[44,61],{"facility":45,"status":11,"city":46,"state":47,"zip":11,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Zhongda Hospital,Affiliated to Southeast University","Nanjing","Jiangsu","China","CN",{"type":51,"coordinates":52},"Point",[53,54],118.77778,32.06167,{"lat":54,"lon":53},[57],{"name":58,"role":40,"phone":59,"phoneExt":11,"email":60},"Lin Liu","13913968688","wenyu811@126.com",{"facility":45,"status":11,"city":46,"state":47,"zip":11,"country":48,"countryCode":49,"cosmosGeoPoint":62,"geoPoint":64,"contacts":11},{"type":51,"coordinates":63},[53,54],{"lat":54,"lon":53},{"type":66,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100649113","phase-1-a-phase-ib-randomized-double-blind-placebo-controlled-study-to-evaluate-the-safety-and-efficacy-of-vc004-capsules-for-pain-in-bone-metastases-100649113",false,"NCT07731685","A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone Metastases","Inclusion Criteria:\n\n1. Participants must understand and voluntarily sign the informed consent form (ICF);\n2. Male or female, aged ≥ 18 years;\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;\n4. Life expectancy of ≥ 12 weeks, as assessed by the investigator;\n5. The participant is able to communicate well with the investigator, and is willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n1. The participant's pain is associated with oncologic emergencies, such as intestinal obstruction\u002Fperforation, spinal cord compression, epidural metastasis, or fracture or impending fracture of weight-bearing bones;\n2. The participant has known or suspected unstable brain metastases or leptomeningeal metastases；\n3. History of severe alcohol, analgesic, or narcotic drug abuse within 6 months prior to screening;\n4. Major surgery within 3 months prior to screening, or planned major surgery during the study period;\n5. Female participants who are planning to become pregnant, are pregnant, or are breastfeeding; or participants who are unwilling or unable to use effective contraception throughout the entire study period and for 3 months after the end of the study;\n6. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.","ALL","18 Years",{"count":76,"type":77},26,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","This is a randomized, double-blind, placebo-controlled Phase Ib study evaluating the safety and efficacy of VC004 capsules for the relief of moderate-to-severe pain associated with bone metastases",[83],"Pain in Bone Metastases","NOT_YET_RECRUITING","2026-07-23",{"date":87,"type":88},"2026-07-28","ACTUAL",{"date":90,"type":77},"2026-07-30",{"date":92,"type":77},"2027-12-30",{"name":5,"class":6},2]